HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-12-01 | Oramed Pharmaceuticals | Hefei Tianhui Incubator of Technologies investment in Post-IPO Equity - Oramed Pharmaceuticals | 50 M USD |
More informations about "Hefei Tianhui Incubator of Technologies"
ๅ่ฅๅคฉ้บฆ็็ฉ็งๆๅๅฑๆ้ๅ ฌๅธ-ๅ่ฅๅคฉ้บฆ็็ฉ็งๆๅๅฑๆ้ๅ ฌๅธ
Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) was founded on June 26, 2012, with a registered capital of 500 million yuan, and a registered address of Hefei Economic and โฆSee details»
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to โฆ
NEW YORK, Aug. 2, 2023 /PRNewswire/ โ Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term โฆSee details»
Hefei Tianhui Incubator of Technologies Co., Ltd. | LinkedIn
Hefei Tianhui Incubator of Technologies Co., Ltd. is a pharmaceuticals company based out of NO. 199 FANHUA ROAD, ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Heifei, โฆSee details»
Oramed Receives Additional $3 Million Milestone Payment from โฆ
JERUSALEM, Jan. 9, 2019 /PRNewswire/ โ Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the โฆSee details»
HTBT - Crunchbase Company Profile & Funding
HTBT is an enterprise dedicated to the introduction and research and development of diabetes series products and technologies, the construction of industrial clusters of protein oral drug delivery platforms, and the provision of โฆSee details»
Chinese Regulatory Authority [NMPA] Approves IND Application โฆ
NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the โฆSee details»
HTIT expects to obtain Chinaโs first oral insulin approval
May 16, 2023 Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT)โs NDA for recombinant human insulin capsule ORMD-0801 for type 2 diabetes is under review by the NMPA and, if โฆSee details»
Oramed Pharmaceuticals Inc., Oramed Ltd. and Hefei Tianhui โฆ
Mar 13, 2019 Oramed Pharmaceuticals Inc., its wholly owned subsidiary, Oramed Ltd. (collectively, the โCompanyโ), and Hefei Tianhui Incubator of Technologies Co. Ltd. (โHTITโ) โฆSee details»
HTIT, Oramed alliance shows need, challenge of China โฆ
Jul 20, 2016 JERUSALEM โ Marking a pivotal moment in the growing relationship between China and Israel, the biggest pharma licensing agreement between the two countries recently โฆSee details»
Oramed announces closing of its previously-announced deal with โฆ
Jan 5, 2016 Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, has announced the closing of its previously-announced license and investment deal with Hefei โฆSee details»
Oramed Inks $50M in Licensing, Investment Deals
Nov 30, 2015 Oramed Pharmaceuticals said today it will generate more than $50 million from licensing and investment deals with Hefei Tianhui Incubator of Technologies (HTIT), in return โฆSee details»
Oramed Announces Xiaoming Gao Joins Board of Directors
Jul 2, 2019 Mr. Gao is the Chairman of Hefei Tianhui Incubator of Technologies Co. Ltd. (โHTITโ), which signed a strategic licensing partnership with Oramed in November 2015 to โฆSee details»
Chinese Regulatory Authority [NMPA] Approves IND Application
Mar 26, 2019 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of โฆSee details»
Hefei Tianhui OK'd to Start China Trials of In-licensed Oral Insulin
Mar 27, 2019 Hefei Tianhui Incubator of Technologies, a Sinopharm affiliate, has been approved to start China clinical trials of its oral insulin product (ORMD-0801). HTIT acquired China rights โฆSee details»
Oramed Pharmaceuticals Inc. Signs License Deal with Hefei Tianhui ...
Nov 30, 2015 The agreement gives Hefei Tianhui Incubator of Technologies Co. Ltd. exclusive rights to market Oramed's oral insulin capsule, ORMD-0801, in China, Hong Kong and Macau. โฆSee details»
The Promising Future of Oral Insulin - Diabetes In Control
Oct 6, 2020 Phase 3 trials will also be initiated by partner Hefei Tianhui Incubator of Technologies Company (HTIT). Practice Pearls: The possibility of oral insulin therapy provides โฆSee details»
Oramed completes China rights agreement | Fierce Pharma
Dec 1, 2015 Israel's Oramed has brought its oral insulin capsule into China, Hong Kong and Macau, signing an agreement this week worth up to $50 million with the Chinese Hefei Tianhui โฆSee details»
Safety, Pharmacokinetics, and Pharmacodynamics of โฆ
Feb 19, 2022 Hefei Tianhui Incubator of Technologies Co., Ltd., Hefei, China. Search for more papers by this author. Guang Ning, Guang Ning. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and โฆSee details»
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Insulin ...
3 Hefei Tianhui Incubator of Technologies Co., Ltd., Hefei, China. PMID: 35182035 DOI: 10.1002/cpdd.1060 Abstract Oral delivery is an ideal method of insulin administration and is โฆSee details»
FDA approves Rexulti as first drug to treat agitation in ... - BioWorld
May 11, 2023 Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT)โs NDA for recombinant human insulin capsule ORMD-0801 for type 2 diabetes is under review by the NMPA and, if โฆSee details»